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Abstract: The bulbs of Allium species are a known source of antibacterial phytochemicals. Anti-
infective, efflux pump and biofilm inhibitory activities of bulb extracts of selected Ghanaian shallots
Allium cepa var aggregatum were evaluated using the HT-SPOTi assay and other whole-cell pheno-
typic screening techniques to determine their possible mechanisms of action. Ethanol and aqueous
extracts of white A. cepa inhibited the growth of Mycobacterium smegmatis mc2 155 and Escherichia
coli, respectively. The majority of the Allium extracts significantly (p < 0.05) exhibited efflux pump
inhibitory activity against all the acid-fast, Gram-positive and Gram-negative strains used. Hexane
and chloroform extract of the pink A. cepa and the aqueous extract of the white A. cepa significantly
inhibited M. smegmatis biofilm formation. For Pseudomonas aeruginosa, the inhibition was observed at
250 µg/mL for the aqueous extract (~77.34%) and 125 µg/mL for the hexane extract (~76.51%). The
results suggest that Ghanaian shallots could potentially be useful when further developed to tackle
antimicrobial resistance, particularly in tuberculosis (TB).
Keywords: tuberculosis; HT-SPOTi; efflux pumps; biofilms; antimicrobial resistance
1. Introduction
A surge in the emergence of multidrug- and extensively-drug-resistant strains of
Mycobacterium tuberculosis, has been linked to the increasing failure of antimicrobial therapy
as a result of irrational use of antibiotics, and non-compliance to conventional treatment.
There is, therefore, renewed research interest in natural products with the hope of discover-
ing new antitubercular leads.
Antimicrobial resistance (AMR) has been named by the World Health Organization
(WHO) as one of the three most important public health threats of the 21st century [1],
and it causes persistent infections that claim millions of lives every year with enormous
demands on medical and social resources. A WHO Interagency Coordination Group report
on AMR estimates that 700,000 people die each year due to antibiotic resistance including
230,000 people who die from multidrug-resistant tuberculosis. This number is projected to
rise to 10 million by 2050 if nothing is done to stop the AMR menace [2,3]. The overuse
and misuse of antimicrobial medications, arbitrary prescribing, and unnecessary use of
antibiotics in agriculture are just some of the causes of AMR. Diminishing numbers of
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new antibiotics in the drug development pipeline has intensified the urgency to develop
new antimicrobials with novel modes of action or resistance-reversal mechanisms for the
treatment of infections.
Biofilms and efflux pumps have been identified as key contributors to AMR. Biofilm-
producing cells are known to be much less susceptible to antimicrobial agents than their
planktonic forms, rendering them to be 1000-fold more resistant to antibacterial agents.
Bacterial efflux pumps are membrane proteins involved in the export of antibiotics from
the bacterial cell, making infections more difficult to treat [4]. Over-expression of efflux
proteins in Mycobacterium species including M. tuberculosis plays an important role in
antibiotic resistance and the development of multidrug resistance (MDR) phenotypes [5,6].
Ojah et al. (2008) [7] hypothesized that biofilm formation in M. tuberculosis could
also be responsible for persistence of Mycobacterium infections. In the same work, M.
tuberculosis and M. smegmatis biofilms were able to tolerate ten times the minimal inhibitory
concentrations of the anti-tuberculosis drugs isoniazid and rifampicin [7]. The simultaneous
use of efflux pump and/or biofilm inhibitors would target bacterial growth and AMR. This
would therefore provide a potential way to improve the treatment of MDR infections.
A significant percentage of newly approved antibacterials are either natural products
or their derivatives [8]. Additionally, hundreds of natural products possessing novel and
known structural architectures have been reported to exhibit activity towards non-resistant
and multidrug-resistant strains of M. tuberculosis. Recent research has reported the activity
of plant natural products that inhibit biofilm formation and efflux pumps in bacteria [9,10].
Ethnopharmacological studies have shown that plants from the Amaryllidaceae family
such as garlic, onions and bulbs of harmattan lily (Crinum jagus) are being used in Ghana
for various respiratory tract conditions such as cough, asthma and even tuberculosis.
This includes Allium sativum (bulb) and Allium cepa (bulb and leaves) [11,12]. Extracts
and isolated compounds from this genus have also shown promising effects as inhibitors
of efflux pumps and bacterial biofilms [13,14]. In 2018 we reported on the efflux pump
inhibition and anti-biofilm activity of disulfides from Allium stipitatum and their synthetic
derivatives on mycobacterial biofilms and efflux pumps [14].
In this study, we investigated the antibacterial, efflux pump and biofilm formation
inhibitory activities of the bulb extracts of Ghanaian Allium cepa var aggregatum pink and
white varieties (shallot) as potentially useful leads in our efforts towards the discovery
and development of new anti-tuberculosis agents. Photos of Allium cepa var aggregatum
white variety (a), white and pink varieties together (b) and the pink variety (c) are shown
in Figure 1 respectively.






Figure 1. Photos of Allium cepa var aggregatum (White) (a); Allium cepa var aggregatum (White and 
Pink varieties together) (b) and Allium cepa var aggregatum (Pink) (c). 
2. Results 
2.1. Phytochemical Screening for the Allium Extracts 
Initial phytochemical screening confirmed the presence of various secondary 
metabolites including condensed tannins, alkaloids, triterpenoids, phytosterols and 
coumarins in majority of the extracts as shown in Table 1. 
Table 1. Phytochemical screening. 
 MeAC HxAC ChAC EtAC AqAC MeACb EaAC 
Tannins Condensed Condensed Condensed Condensed Condensed Condensed Condensed 
Saponins + − + + + + + 
Flavonoids + − − + − + − 
Reducing sugars + − + + + + + 
Alkaloids + + + + + +− − 
Triterpenoids + + + + + + + 
Phytosterols + + + + + + + 
Coumarins + + + + + + + 
Key: + Detected. − Not detected. Allium cepa var aggregatum extracts (Pink: MeAC-methanol, HxAC-hexane, ChAC-
chloroform, EtAC-ethanol; White: AqAC-aqueous, MeACb-methanol, EaAC-ethanol). 
2.2. Allium Extracts Demonstrated Antibacterial Growth Inhibition 
The antibacterial activity of the Allium extracts was evaluated by determining the 
minimum inhibitory concentration (MIC) (Table 2). Extracts were moderately effective at 
different concentrations against the pathogens used (MIC values ranged between 250–500 
µg/mL). Escherichia coli was sensitive to the methanol extract of pink A. cepa, methanol and 
aqueous extract of white A. cepa with the aqueous extract of the white A. cepa having the 
highest inhibitory effect (MIC-250 µg/mL). At a concentration of 500 µg/mL, the methanol 
extract of pink A. cepa and ethanol and aqueous extract of white A. cepa inhibited the 
growth of P. mirabilis. Methanol extracts of pink A. cepa at 250 µg/mL and ethanol and 
hexane extracts at 500 µg/mL inhibited S. aureus. For K. pneumoniae and S. typhi, which 
Figure 1. Photos of Allium cepa var aggregatum (White) (a); Allium cepa var aggregatum (White and
Pink varieties together) (b) and Allium cepa var aggregatum (Pink) (c).
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2. Results
2.1. Phytochemical Screening for the Allium Extracts
Initial phytochemical screening confirmed the presence of various secondary metabo-
lites including condensed tannins, alkaloids, triterpenoids, phytosterols and coumarins in
majority of the extracts as shown in Table 1.
Table 1. Phytochemical screening.
MeAC HxAC ChAC EtAC AqAC MeACb EaAC
Tannins Condensed Condensed Condensed Condensed Condensed Condensed Condensed
Saponins + − + + + + +
Flavonoids + − − + − + −
Reducing
sugars + − + + + + +
Alkaloids + + + + + +− −
Triterpenoids + + + + + + +
Phytosterols + + + + + + +
Coumarins + + + + + + +
Key: + Detected. − Not detected. Allium cepa var aggregatum extracts (Pink: MeAC-methanol, HxAC-hexane, ChAC-chloroform, EtAC-
ethanol; White: AqAC-aqueous, MeACb-methanol, EaAC-ethanol).
2.2. Allium Extracts Demonstrated Antibacterial Growth Inhibition
The antibacterial activity of the Allium extracts was evaluated by determining the
minimum inhibitory concentration (MIC) (Table 2). Extracts were moderately effective
at different concentrations against the pathogens used (MIC values ranged between
250–500 µg/mL). Escherichia coli was sensitive to the methanol extract of pink A. cepa,
methanol and aqueous extract of white A. cepa with the aqueous extract of the white A. cepa
having the highest inhibitory effect (MIC-250 µg/mL). At a concentration of 500 µg/mL,
the methanol extract of pink A. cepa and ethanol and aqueous extract of white A. cepa
inhibited the growth of P. mirabilis. Methanol extracts of pink A. cepa at 250 µg/mL and
ethanol and hexane extracts at 500 µg/mL inhibited S. aureus. For K. pneumoniae and
S. typhi, which were not sensitive to amoxicillin (MIC->500 µg/mL), only the ethanol
extract of pink A. cepa was effective: K. pneumoniae (MIC-500 µg/mL) while the white A.
cepa aqueous extract inhibited S. typhi (MIC-500 µg/mL). The P. aeruginosa was sensitive to
all the extracts with the exception of the aqueous extract of the white A. cepa. The methanol
extract of the pink A. cepa gave the highest activity at a concentration of 250 µg/mL with
the other extracts at a concentration of 500 µg/mL. In the case of S. epidermidis, the ethanol,
methanol and chloroform extract of pink A. cepa and the methanol extract of white A. cepa
had an inhibitory effect at 500 µg/mL. The Mycobacterium strain M. smegmatis was sensitive
to the ethanol extract of the pink A. cepa at a concentration of 250 µg/mL. However, the
rest of the extracts showed no activity.
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Table 2. Effect of extracts of Allium cepa on the growth of microorganisms.
Minimum Inhibitory Concentration MIC (µg/mL)
E. coli P. mirabilis S. aureus K. pneumoniae P. aeruginosa S. typhi S. epidermidis M. smegmatis
MeAC 500 500 250 >500 250 >500 500 >500
EtAC >500 >500 500 500 500 >500 500 250
HxAC >500 >500 500 >500 500 >500 >500 >500
ChAC >500 >500 >500 >500 500 >500 500 >500
MeACb 500 >500 >500 >500 500 >500 500 >500
EaAC >500 500 >500 >500 >500 >500 500 >500
AqAC 250 500 >500 >500 500 500 500 >500
Ciprofloxacin <0.49 <0.49 <0.49 <0.49 <0.49 7.81 <0.49 <0.49
Amoxicillin 15.6 62.5 62.5 >500 62.5 >500 7.81 NT
Rifampicin NT NT NT NT NT NT NT 7.81
Key: NT = Not tested. Allium cepa var aggregatum extracts (Pink: MeAC-methanol, HxAC-hexane, ChAC-chloroform, EtAC-ethanol; White:
AqAC-aqueous, MeACb-methanol, EaAC-ethanol). Extracts showing activity.
2.3. Allium Extracts Demonstrate Efflux Pump Inhibitory Effect
The efflux pump inhibition assay was used to evaluate the activity of the extracts
using ethidium bromide (EtBr) as a substrate. This assay is based on the principle that EtBr
has a strong fluorescence property intracellularly. It binds to DNA to give an increasing
fluorescence following continual accumulation. When accumulated within the bacterial
cells, fluorescence intensity increases, giving an indication of the inhibition of the efflux
pump mechanism within the cells [14]. In the absence of an efflux pump inhibitory activity,
the cell pumps out EtBr, resulting in a low fluorescence measurement. The accumulation
assay was performed with sub-MIC concentration of the extracts ( 12 MIC). The results
revealed that the extracts significantly (p-value < 0.05) enhanced the accumulation of EtBr
to different levels when compared to the control with no efflux pump inhibition. This
confirms their inhibitory activity against bacterial efflux pumps. The methanolic extract of
the pink A. cepa was the only extract that showed no significant activity in the M. smegmatis
strain (Figure 2a) (p-value > 0.05). However, all the extracts of white A. cepa significantly
enhanced the accumulation of EtBr (Figure 2b). All extracts significantly enhanced EtBr
accumulation in P. aeruginosa (Figure 3). The effect of efflux pump inhibition in S. aureus
(Figure 4a) was statistically significant for all the extracts of the pink A. cepa. Extracts of the
white A. cepa also showed a significant inhibitory effect, with the exception of the methanol
(Figure 4b). The chloroform extract of the pink A. cepa had a greater efflux pump inhibitory
activity in the M. smegmatis and P. aeruginosa strain than the other plant extracts. The hexane
extract of the pink variety of A. cepa is seen to have the strongest activity among the extracts
in the S. aureus strain (Figure 4a). Its effect is statistically (p-value < 0.05) comparable to
that of chlorpromazine, a known efflux inhibitor in S. aureus.
The standard efflux pump inhibitor verapamil exhibited a very good efflux pump
inhibitory activity in all the bacterial cells followed by chlorpromazine.
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plate method (results not shown). For better biofilm formation we recommend that TSB 
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2.5. Allium Extracts Demonstrate Biofilm Inhibition 
Biofilm formation contributes to bacterial persistence, which contributes to anti-
microbial resistance. Hence, the A. cepa extracts were evaluated to find out if they have a 
biofilm inhibitory effect. The different Allium extracts showed varying levels of biofilm 
inhibition at different concentrations. The biofilm inhibition of the extracts on the P. 
aeruginosa and M. smegmatis biofilms were concentration-dependent. A good inhibition of 
biofilm formation was observed for M. smegmatis. Compared to the other extracts, the 
hexane and chloroform extract of the pink A. cepa and the aqueous extract of the white A. 
cepa had significant inhibition on the M. smegmatis biofilm (Figure 6A). The hexane extract 
gave the highest inhibitory effect in all the concentrations used. The aqueous extract of the 
white A. cepa and the hexane extract of the pink A. cepa had a greater inhibitory effect in 
P. aeruginosa biofilm formation (Figure 6B). The highest inhibition was observed at 250 
µg/mL for the aqueous extract (~77.34%) and 125 µg/mL for the hexane extract (~76.51%). 
All the other extracts moderately inhibited biofilm formation in P. aeruginosa at 
concentrations of 125 µg/mL and 250 µg/mL. Unlike the M. smegmatis and P. aeruginosa 
strains, the S. aureus strain was less susceptible to biofilm inhibition by the extracts. 
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high in the TSB medium supplemented with additional glucose to 1% than the medium
without glucose supplement (Figure 5). Similar results were observed in the microtitre
plate method (results not shown). For better biofilm formation we recommend that TSB be
supplemented with additional glucose.
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Figure 5. Biofilm f rmation by (A) S. aureus + glucose; (B) P. aeruginosa + gl cose; (C) M. smegm tis + lucose;
(D) S. aureus; (E) P. aeruginosa; (F) M. smegmatis.
2.5. Allium Extracts Demonstrate Biofilm Inhibition
Biofilm formation ontributes to bact rial persiste ce, which contributes to anti-
microbial resistance. Hence, the A. cepa extracts were evaluated to find out if they have
a biofilm inhibitory effect. The different Allium extracts showed varying levels of biofilm
inhibition at different concentrations. The biofilm inhibition of the extracts on the P. aerugi-
nosa and M. smegmatis biofilms were concentration-dependent. A good inhibition of biofilm
formation was observed for M. smegmatis. Compared to the other extracts, the hexane and
chloroform extract of the pink A. cepa and the aqueous extract of the white A. cepa had
significant inhibition on the M. smegmatis biofilm (Figure 6A). The hexane extract gave the
highest inhibitory effect in all the concentrations used. The aqueous extract of the white
A. cepa and the hexane extract of the pink A. cepa had a greater inhibitory effect in P. e ugi-
nosa biofilm formation (Figure 6B). The highest inhibition was observed at 250 µg/mL for
the aqueous extract (~77.34%) and 125 µg/mL for the hexane extract (~76.51%).
All the other extracts moderately inhibited biofilm for ation in P. aeruginosa at con-
centrations of 125 µg/mL and 250 µg/mL. Unlike the M. smegmatis and P. aeruginosa strains,
the S. aureus strain was less susceptible to biofilm inhibition by the extracts. However, the
hexane extract of pink A. cepa was significantly effective at inhibiting S. aureus biofilms
(~69.3%). The aqueous extract f white A. cepa was also effective at inhibiting biofilm
formation at a sub-inhibitory concentration of 62.5 µg/mL (~66.8%) (Figure 6C).
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3. Discussion
The minimum inhibitory concentration determined from the HT-SPOTi assay showed
that extracts of both white and pink A. cepa had a broad spectrum of activity on the Gram-
positive and Gram-negative strains at different concentrations. Methanolic and ethanolic
extracts of the pink A. cepa and the aqueous extract of the white A. cepa showed high
activity on most of the pathogens. Overall, P. aeruginosa was more sensitive to all the
extracts with the exception of the aqueous extract of the white A. cepa. The methanol
extract of the pink A. cepa gave the highest activity (MIC-250 µg/mL) while the other
extracts (MIC-500 µg/mL). The aqueous extract was the most effective among the white
A. cepa, inhibiting four pathogens, MIC-250 µg/mL for E. coli and 500 µg/mL for P. mirabilis,
P. aeruginosa and S. typhi, respectively. Ethanolic extract of white A. cepa had no activity
on the pathogens except for P. mirabilis (500 µg/mL). In as much as K. pneumoniae and
P. mirabilis are intrinsically insensitive to antibiotics, it is worth noting that some extracts
inhibited their growth at 500 µg/mL. Only the ethanol extract of the white A. cepa inhibited
the growth of M. smegmatis with an MIC of 250 µg/mL; even though the activity is moderate,
this highlights the need to further explore the extract as a potential antimycobacterial agent
since the treatment of mycobacterial infections (notably M. tuberculosis) is being threatened
by multidrug-resistant strains [6].
In the bacterial efflux pump inhibition assay, the majority of the Allium extracts
significantly enhanced the accumulation of ethidium bromide in all the strains when
compared to the control with no drug. The results suggest that A. cepa extracts possess
an efflux pump inhibitory activity, hence interfering with ethidium bromide efflux from the
bacteria cells that express multiple efflux proteins. This indicates their potential as efflux
pump inhibitors. Similar results of efflux pump inhibition by Allium plants have been
reported; Extracts of A. sativum and allyl sulfide (a bioactive component of most Allium
plants) have been shown to inhibit the multidrug efflux pump EmrD-3 of V. cholerae [13].
Disulfides from A. stipitatum have also been found to have efflux pump inhibitory activity
against Mycobacterium strains [14]. Interestingly, some of the Allium extracts, which did
not show antimicrobial activity (MIC > 500 µg/mL) especially in M. smegmatis, were able
to inhibit efflux pump activity. These further support the claims that plant extracts are
excellent candidates for lead optimization of efflux pump inhibitors [15]. In general, it
was observed that the less polar solvent extracts had good activity than the more polar
extracts. Drug efflux by efflux pumps is a contributing factor in the growing problem
of antimicrobial resistance contributing to the intrinsic and acquired resistance in a wide
variety of bacteria. This keeps complicating the treatment of infectious diseases [16,17].
Therefore, the Ghanaian Allium cepa var aggregatum plant demonstrating to have efflux
pump inhibitory properties could have the potential of restoring the bacterial susceptibility
to drugs and enhance the treatment of infectious diseases. Further work is underway to
isolate and identify the bioactive compounds and also ascertain the modulatory effect of
these extracts on drugs in clinical use.
Bacterial biofilms have contributed greatly to the persistence of antimicrobial resis-
tance. They have also become a major leading cause of multi-drug resistance. In the present
report, the different extracts of white and pink A. cepa varieties inhibited Gram-positive,
Gram-negative and Mycobacterium biofilms at sub-lethal concentrations. The ability of
each extract to inhibit biofilm formation was dependent on the type of solvent and the
concentration of the extract used. Overall, non-polar hexane extract of the pink variety
of A. cepa and the aqueous extract of the white variety inhibited biofilm formation in
all strains of bacteria. The biofilm inhibition activity of the extracts against P. aeruginosa
and M. smegmatis were dose-dependent. The underlying mechanisms of the antibiofilm
properties of these extracts could be due to, inhibiting the formation of the polymer matrix,
suppressing cell adhesion and attachment, interrupting extracellular matrix generation
and/or decreasing virulence factors production. These mechanisms have accounted for
biofilm inhibition properties of natural products according to Lu et al. in 2019 [18]. In
recent years, the antibiofilm properties of Allium species have attracted attention. For
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example, the biofilm inhibition properties of A. sativum, A. stipitatum, A. orientale and
A. porrum have been documented [19–22]. The inhibition of bacterial efflux pumps has also
been suggested as a strategy to inhibit biofilm formation [23].
It is, therefore, noteworthy that the Ghanaian A. cepa var aggregatum extracts have
demonstrated both efflux pump and biofilm inhibitory properties which are interesting
since a major challenge in the management and emergence of multidrug-resistant tubercu-
losis is the long duration of treatment. Expression of efflux proteins and biofilm formation
has been recognized as a common mechanism contributing to both virulence and drug
tolerance in M. tuberculosis [24]. Richards and Ojha (2014) [25] reported that Mycobacterium
biofilms enhance the spontaneous growth of mycobacteria, particularly M. tuberculosis,
and also promotes persistence against exogenous threats. This confers drug resistance to
drug-susceptible M. tuberculosis mutants [25].
The ability of the extracts to inhibit efflux pumps and biofilm formation in M. smegmatis
indicates their potential to mitigate M. tuberculosis by their pleiotropic mode of action or by
their ability to possibly reverse resistance by improving sensitivity when combined with
existing antibacterials that have lost their sensitivity due to antibiotic resistance.
4. Materials and Methods
4.1. Materials
Chlorpromazine, verapamil, rifampicin, ciprofloxacin, EtBr and phosphate-buffered
saline (PBS) tablets (0.01 M phosphate buffer, 0.0027 M potassium chloride and
0.137 M sodium chloride, pH 7.4) were purchased from Sigma-Aldrich, St Louis, MO, USA.
Middlebrook 7H10 agar, Middlebrook 7H9 broth, oleic acid-albumin-dextrose-catalase
(OADC) supplement and albumin–dextrose–catalase (ADC) supplement were purchased
from Difco, Franklin Lakes, NJ, USA. Tryptic soy broth (TSB) (HiMedia, Mumbai, India)
was used for the anti-biofilm assay. All solutions were prepared in distilled water or DMSO
on the day of the experiment.
4.2. Collection of Plant Material and Extraction
The pink and white varieties of the bulbs of Ghanaian shallot (Allium cepa var aggregatum)
were purchased from Keta in the Volta region of Ghana (5◦55′19.5384” N 0◦59′31.8948” E) on
13 April 2019. Dr. George Henry Sam, Department of Herbal Medicine, KNUST, Ghana
authenticated the plant materials, and voucher specimens (Pink Allium cepa var aggre-
gatum-KNUST/2019/HM1/013; White Allium cepa var aggregatum-KNUST/2019/HM1/
014) were kept in the Herbarium. The fresh bulbs were washed thoroughly and blended
with an Akai (Tokyo, Japan) electric blender (Model no. BD033A SO4M) using hexane,
chloroform, ethanol, methanol and water as solvents. The extracts were filtered, and the
solvents evaporated using a rotary evaporator (Buchi Rotavapor R-210, BÜCHI Labortech-
nik AG CH-9230 Flawil 1, Switzerland) to yield semi-solid dark brown extracts. All the
extracts were stored in a fridge at −4 ◦C until used.
4.3. Microbial Strains and Culture Conditions
The following microbial strains were used in this study: Escherichia coli (ATCC 25922),
Staphylococcus aureus (ATCC 25923), Pseudomonas aeruginosa (ATCC 4853); clinical strains
of Salmonella typhi, Klebsiella pneumoniae, Staphylococcus epidermidis, Proteus mirabilis; and
Mycobacterium smegmatis mc2 155 (ATCC 19420), a fast-growing mycobacteria used as
a surrogate for M. tuberculosis. The pathogens were obtained from the Department of
Pharmaceutical Microbiology, and the Cell Culture Laboratory, Department of Pharmacol-
ogy, KNUST. Glycerol stocks of the microorganisms were stored at −80 ◦C. Nutrient agar
(Oxoid, Basingstoke, England) was used to culture the Gram-positive and Gram-negative
bacteria and fungus while Middlebrook 7H10 agar supplemented with OADC was used
for M. smegmatis.
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4.4. Methods
4.4.1. Antimicrobial Susceptibility Assay with HT-SPOTi
The minimum inhibitory concentrations (MIC) of the different extracts of cepa varieties
were determined using the high-throughput spot culture growth inhibition (HT-SPOTi)
assay as described by Danquah et al. (2016) [26]. Two-fold serial dilutions of a stock
concentration of the extracts (50 mg/mL) were done in a PCR half-skirted 96-well plate to
give a concentration range of 50–0.05 mg/mL. A volume (2 µL) of the drug dilution was
transferred into a corresponding 96-well plate and 200 µL of molten agar was dispensed
into it with shaking (nutrient agar was used for the bacteria and fungus, and Middlebrook
7H10 agar with 0.5% (v/v) glycerol supplemented with 10% OADC for the Mycobacterium
strain). The plate was left to solidify. A volume of 2 µL of the bacterial suspension
containing ~1 × 106 cfu/mL was spotted onto each well of the 96-well plate. The bacterial
spot suspension was absorbed into the agar (approximately 5 min). The plate was sealed
with parafilm, wrapped with aluminum foil and incubated at 37 ◦C for 18–48 h based on the
doubling time of the bacterial models used in this study. Wells with no drug were added to
serve as growth control. Ciprofloxacin, a broad-spectrum antibiotic of the fluoroquinolone
class, which is bactericidal and inhibits topoisomerase II (DNA gyrase) and amoxicillin,
a broad-spectrum penicillin which is bactericidal and inhibits bacterial cell wall synthesis-
were used as drug control for Gram-positive and Gram-negative bacteria. Rifampicin,
a first-line TB drug was used for the acid-fast bacteria, Mycobacterium. The minimum
inhibitory concentration (MIC) was defined as the lowest concentration of antimicrobial
agent that inhibited visible bacterial growth within the incubation period. The test was
done in triplicate.
4.4.2. Efflux Pump Inhibitory Assay
The whole-cell phenotypic efflux pump inhibition assay was performed according
to previously published protocols with some modification using M. smegmatis, S. aureus
and P. aeruginosa [27–30]. The Gram-positive and Gram-negative cells were cultured in
10 mL nutrient broth while the Mycobacterium was cultured in Middlebrook 7H9 broth
(Difco, USA) in Erlenmeyer flasks containing 10% OADC enrichment (Becton Dickinson,
Franklin Lakes, NJ, USA) and 0.05% Tween 80. They were cultured at 37 ◦C with shaking
at 150 rpm until an optical density of 600 nm (OD600) of 0.8–1 (mid-log phase). The OD600
of the cultures was adjusted to 0.4 after which 10 mL was centrifuged at 3000 rpm for
10 min. The supernatant was discarded, and pellets washed with sterile PBS.
The pellets were re-suspended in 10 mL of sterile PBS. The bacteria suspension
(500 µL) (Test) and 500 µL of PBS (Blank) were pipetted into 2 mL Eppendorf tubes
and glucose added to a final concentration of 0.4%. Different concentrations of the extracts
and compounds were added at half their MIC’s. The suspension was vortexed to distribute
the cells uniformly. Aliquots of 100 µL from each mixture were transferred into 96-well
plates (in triplicates) and 5 µL of EtBr added to give a final concentration of 0.5 mg/L.
The EtBr was added just before reading the fluorescence intensity. The fluorescence was
measured using the microplate reader (Biotek Synergy H1 Hybrid Multi-Mode Reader:
271230, Vermont, VT, USA) at 530 nm (excitation) and 585 nm (emission) every 10 min over
a period of 60 min at 37 ◦C. This measures the effect of the extracts on the accumulation of
EtBr within the cells by inhibiting the efflux pumps. The known efflux pump inhibitors,
verapamil and chlorpromazine, served as reference drugs and a drug-free culture was used
as control.
4.4.3. Biofilm Inhibition Assay
Evaluation of Biofilm Forming Potential
The biofilm-forming ability of M. smegmatis, P. aeruginosa and S. aureus was evaluated
by the tube method [31] and the microtitre-plate method [32] with minor modifications
described below.
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Tube Method
The tube method is a qualitative assay for the detection of microorganisms that
produce biofilm. It is based on the occurrence of a visible film adhering to the surface of
the tube. As described by Christensen et al. in 1985 [31], bacterial isolates were inoculated
in a polystyrene test tube that contained 5 mL of TSB and incubated at 37 ◦C for 24 h.
Cultures supplemented with glucose to a concentration of 1% was included for com-
parison. The contents were decanted, the tubes washed twice with phosphate-buffered
saline and left to dry. Subsequently, the polystyrene tubes were stained with crystal violet
(0.1%) for 15 min, rinsed with PBS and air-dried in an inverted position. The occurrence of
visible film lined the walls, and the bottom of the tube indicates biofilm production [31].
The tests were carried out in triplicate.
Microtitre-Plate Method
The biofilm-forming potential of the microorganisms was quantitatively analyzed
using the microtitre-plate biofilm formation assay as previously described with some
modifications [32–34]. Briefly, a loopful of an overnight culture of the microorganisms
were inoculated in 5 mL Tryptone Soy Broth (TSB) and incubated at 37 ◦C for 24 h with
shaking at 150 rpm. The cultures were 1:100 diluted in TSB (supplemented with additional
glucose to a final concentration of 1%) after incubation, and 100 µL of each diluted culture
pipetted into a 96-well flat-bottom microtitre plate (Star Lab, Humberg, Germany). Plates
were covered and incubated at 37 ◦C. After 24 h, the planktonic cells were aspirated, and
wells were washed with PBS to remove planktonic bacteria.
Adherent bacterial biofilms were fixed by drying in the incubator for 30 min and
stained with 125 µL of 0.1% (w/v) crystal violet (Burgoyne Burbidges and Co, Mumbai,
India) for 10 min at room temperature. Excess stain was washed with distilled water and
left to air dry. Subsequently, the stain was solubilized with 125 µL of 95% ethanol and
left for 10 min. The optical density of each well was measured at 600 nm (OD600) using
an automated plate reader (Biotek Synergy H1 Hybrid Multi-Mode Reader: 271230).
Inhibition of Biofilm Formation
The ability of the Allium extracts to inhibit biofilm formation was measured using the
microtiter plate-based assay as described. A volume (180 µL) of each diluted culture was
pipetted into a 96-well flat-bottom microtitre plate. Two-fold serial dilutions of the extracts
were made with Tryptic soy broth (TSB) to achieve sub-minimum inhibitory concentrations
ranging from 250–15.63 µg/mL. An amount (20 µL) of the extract’s solution was then
pipetted into each of the 96-well plates. The plates were incubated undisturbed for 24 h at
37 ◦C. Wells containing only microorganisms were included to serve as the growth control.
After 24 h of incubation at 37 ◦C, the supernatant was collected and the plates were washed,
fixed and stained as described above. The optical density of each well was measured at
600 nm (OD600) using an automated plate reader. The bioassay was performed in duplicate.
The mean absorbance of the samples was determined, and the percentage inhibition of
biofilm was calculated using the equation:







GraphPad prism 8.0 software was used for the statistical analysis using One-Way
Analysis of Variance (ANOVA). Results were quantified as mean ± SEM. Statistical differ-
ences between mean values were performed with Dunnett’s Multiple Comparison Test at
p < 0.05.
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5. Conclusions
The findings from this study showed that the bulbs of Ghanaian Allium cepa var
aggregatum (shallots) are a potential source of phytochemical hits to tackle antimicrobial
resistance as a result of their inhibition of whole-cell efflux pumps, biofilm formation and
antibacterial selectivity against M. smegmatis resistance mechanisms. Bioactivity-guided
isolation and characterization of compounds from these species could lead to the discovery
of lead bioactive compounds that can be developed as drugs for clinical use.
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